The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
O'ConnorO.A.StewartA.K.ValloneM.A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res.2009; 15(22): 7085–7091.
2.
AlsinaM.TrudelS.FurmanR.R.A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res.2012; 18(17): 4830–4840.
3.
Kyprolis [package insert].San Francisco, CA: Onyx Pharmaceuticals. September 2012. http://www.kyprolis.com/Content/pdf. Accessed September 18, 2012.
4.
RaviV.WangM.KaufmanJ.An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood.2012; 119(24): 5661–5669.
GriggsJ.L.ManguP.B.AndersonH.Appropriate chemotherapy dosing for obese patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol.2012; 30(99): 1–10.
7.
GianniL.LladoA.BianchiG.Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol.2010; 28(7): 1131–1137.
8.
AgusD.B.SweeneyC.J.MorrisM.J.Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol.2007; 25(6): 675–681.
9.
CortésJ.FumoleauP.BianchiG.Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol.2012; 30(14): 1594–1600.
10.
GordonM.S.MateiD.AghajanianC.Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol.2006; 24(26): 4324–4332.
11.
HerbstR.S.DaviesA.M.NataleR.B.Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res.2007; 13(20): 6175–6181.
12.
Sebastian de BonoJ.BellmuntJ.AttardG.Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. J Clin Oncol.2007; 25(3): 257–262.
